Response to erlotinib in a patient with treatment refractory chordoma

Anti-Cancer Drugs

Volumn 20, Issue 10, 2009, Pages 953-955

  Singhal, Nimit ^a   Kotasek, Dusan ^a   Parnis, Francis X ^a  

^a Adelaide Cancer Centre   (Australia)

Author keywords

Chordoma; Epidermal growth factor receptor; Epidermal growth factor receptor tyrosine kinase inhibitors; Erlotinib; Imatinib

Indexed keywords

CYT 997; ERLOTINIB; IMATINIB; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ADULT; ARTICLE; BONE PAIN; CANCER RECURRENCE; CASE REPORT; CHORDOMA; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RASH; SYMPTOM;

ANTINEOPLASTIC AGENTS; CHORDOMA; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SACROCOCCYGEAL REGION;

EID: 73349107416     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328330c7f0     Document Type: Article

References (9)

1. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol 2007; 19:367-370.
2. Casali PG, Stacchiotti S, Messina A, Tamborini E, Martini C, Ripamonti C, et al. Imatinib mesylate in 18 advanced chordoma patients [Abstract]. J Clin Oncol 2005; 23 (Suppl):9012.
3. Stacchiotti S, Ferrari S, Ferraresi V, Grignani G, Crippa F, Messina F, et al. Imatinib mesylate in advanced chordoma: a multicenter phase II study [Abstract]. J Clin Oncol 2007; 25 (Suppl):10003.
4. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 2006; 29:572-574.
5. Linden O, Stenberg L, Kjellen E. Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncol 2008; 27:1-2.
6. Weinberger PM, Yu Z, Kowalski D, Joe J, Manger P, Psyrri A, et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 2005; 131:707-711.
7. Orzan F, Terreni MR, Longoni M, Boari N, Mortini P, Doglioni C, et al. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas. Oncol Rep 2007; 18:249-252.
8. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006; 12:6920-6928.
9. Ostroumov E, Hunter CJ. Identifying mechanisms for therapeutic intervention in chordoma: c-met oncoprotein. Spine 2008; 33:2774-2780.